PPARG and congestive heart failure: TZD pharmacology has generally been thought to require direct activation of the nuclear transcription factor PPARγ and, since it is now generally accepted that activation of PPARγ drives the side effects of this class of agents (e.g., increased adiposity, volume expansion, bone loss and congestive heart failure), there has been no clear path forward to create new, more useful insulin sensitizers [4].